Review examines synthetic routes toward goniomitine from 1991 to 2023, highlighting divergent strategies to build its angular tetracyclic architecture.
Goniomitine is of the aspidosperma alkaloid family, with an angularly fused tetracyclic skeleton housing an all‐carbon quaternary carbon chiral center alongside an aminal functional group. This natural product has garnered attention as a synthetic target due to its intriguing molecular architecture and anti ‐proliferative activity in recent years. Following the first synthesis of (−)‐goniomitine by Takano in 1991, synthetic chemists have developed various methods. This review provides an overview of the methodologies used in the synthesis of goniomitine in racemic and enantiopure forms via divergent construction indole framework, indole functionalization, and the integrated oxidation/reduction/cyclization ( iORC ) sequence from 1991 to 2023.
No takes yet. Share an insight, caveat, or question.
Cong‐Bin Ji (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: